drugset / Trial / NCT02094625
NAC to Prevent Cisplatin-induced Hearing Loss
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing and also how well tolerated NAC is when combined with chemotherapy.
Timeline
- Start
- 2016-03
- Primary completion
- 2020-09
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 225 mg/kg | Intravenous |
| Subject | N-acetylcysteine | Small molecule | 300 mg/kg | Intravenous |
| Subject | N-acetylcysteine | Small molecule | 375 mg/kg | Intravenous |
| Subject | N-acetylcysteine | Small molecule | 450 mg/kg | Intravenous |